- Iridex Corp. seems to be at the initial stage of a growth inflection that could drive the stock up 175-625%.
- IRIX has a commercial product which could revolutionize glaucoma treatment, with an addressable market of $1.2 bil+.
- There are several catalysts to drive IRIX stock to fair value, including my projection of revenue growth as the company's system gains traction in the market.
- Due to IRIX's small size, strong products, and undervaluation, I believe the company is a prime acquisition target.
For further details see:
Iridex To Benefit From New Revolutionary Glaucoma Treatment